Patents by Inventor J. J. Wright

J. J. Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl sulfonamides
    Patent number: 8211896
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: July 3, 2012
    Assignee: Chemocentryx, Inc.
    Inventors: Solomon Ungashe, Zheng Wei, J. J. Wright, Andrew Pennell
  • BIS-ARYL SULFONAMIDES
    Publication number: 20100227902
    Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
    Type: Application
    Filed: May 14, 2010
    Publication date: September 9, 2010
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Solomon Ungashe, Zheng Wei, J. J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
  • Inhibitors of human tumor-expressed CCXCKR2
    Patent number: 7649011
    Abstract: Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: January 19, 2010
    Assignee: Chemocentryx, Inc.
    Inventors: Anita Melikian, Jennifer Burns, Brian E. McMaster, Thomas Schall, J. J. Wright
  • Aryl Sulfonamides
    Publication number: 20090163498
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: June 11, 2008
    Publication date: June 25, 2009
    Applicant: CHEMOCENTRYX, INC.
    Inventors: Solomon Ungashe, J. J. Wright, Andrew Pennell, Zheng Wei, Anita Melikan
  • Aryl sulfonamides
    Patent number: 7420055
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: May 13, 2004
    Date of Patent: September 2, 2008
    Assignee: Chemocentryx, Inc.
    Inventors: Solomon Ungashe, J. J. Wright, Andrew Pennell, Zheng Wei, Anita Melikan
  • Bis-aryl sulfonamides
    Patent number: 7227035
    Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: June 5, 2007
    Assignee: Chemocentryx
    Inventors: Solomon Ungashe, Zheng Wei, J. J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
  • Bicyclic compounds as inhibitors of chemokine binding to US28
    Patent number: 7101894
    Abstract: Methods for treating CMV or a CMV-related disease are provided that use compounds having the formula: wherein Ar is a substituted or unsubstituted 5–14 membered heteroaryl group having from 1 to 5 heteroatoms as ring members; R1 is selected from the group consisting of substituted or unsubstituted aryl(C1–C4)alkyl, heteroaryl(C1–C4)alkyl, —C(O)R11, and —C(O)NR11R12, wherein each R11 and R12 independently is substituted or unsubstituted aryl, substituted or unsubstituted aryl(C1–C4)alkyl, substituted or unsubstituted (C4–C8)cycloalkyl(C1–C4)alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl(C1–C4)alkyl and substituted or unsubstituted hetero(C4–C8)cycloalkyl(C1–C4)alkyl; R2 is H or (C1–C8)alkyl; and ZN is a substituted or unsubstituted hetero(C6–C10)bicycloalkyl group.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: September 5, 2006
    Assignee: ChemoCentryx, Inc.
    Inventors: Brian E. McMaster, Thomas J. Schall, Mark Penfold, J. J. Wright, Daniel J. Dairaghi
  • Bis-aryl sulfonamides
    Publication number: 20050137179
    Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
    Type: Application
    Filed: May 19, 2004
    Publication date: June 23, 2005
    Inventors: Solomon Ungashe, Zheng Wei, J. J. Wright, Andrew Pennell, Brett Premack, Thomas Schall
  • Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
    Publication number: 20050075364
    Abstract: This invention provides compounds of Formula I, including pharmaceutically accceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Application
    Filed: June 18, 2004
    Publication date: April 7, 2005
    Inventors: Kap-Sun Yeung, Michelle Farkas, John Kadow, Nicholas Meanwell, Malcolm Taylor, David Johnston, Thomas Coulter, J. J. Wright
  • Arylamines as inhibitors of chemokine binding to US28
    Patent number: 6821998
    Abstract: Methods for treating CMV and CMV-related diseases are provided that use compounds having the formula: wherein the subscripts m and n are each independently integers from 1 to 2; and the R groups are as defined in the specification.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: November 23, 2004
    Assignee: ChemoCentryx, Inc.
    Inventors: Brian E. McMaster, Thomas J. Schall, Mark Penfold, J. J. Wright, Daniel J. Dairaghi
  • Aryl sulfonamides
    Publication number: 20040171654
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: November 17, 2003
    Publication date: September 2, 2004
    Inventors: Solomon Ugashe, Zheng Wei, J. J. Wright, Andrew Pennell
  • Bicyclic compounds as inhibitors of chemokine binding to US28
    Publication number: 20030149055
    Abstract: Methods for treating CMV or a CMV-related disease are provided that use compounds having the formula: 1
    Type: Application
    Filed: August 29, 2002
    Publication date: August 7, 2003
    Applicant: ChemoCentryx
    Inventors: Brian E. McMaster, Thomas J. Schall, Mark Penfold, J. J. Wright, Daniel J. Dairaghi